Anti-follicle stimulating hormone receptor antibodies and methods of treatment
Summary
USPTO granted Patent US12595293B2 to The Wistar Institute covering isolated antibodies and antigen-binding fragments that specifically bind to Follicle Stimulating Hormone Receptor (FSHR), along with methods for treating diseases by administering these antibodies. The patent includes 14 claims and covers compositions for cancer treatment applications.
What changed
USPTO issued Patent No. US12595293B2 for anti-FSHR antibodies developed by inventors Alfredo Perales-Puchalt and David B. Weiner at The Wistar Institute. The patent grants exclusive rights to isolated antibodies that specifically bind to the follicle stimulating hormone receptor, as well as methods of treating diseases by administering these antibody compositions.
For pharmaceutical companies and biotechnology firms developing antibody therapeutics targeting FSHR or related cancer immunotherapies, this patent establishes intellectual property barriers requiring licensing negotiations or design-around strategies. Researchers and developers in the oncology and reproductive health spaces should conduct freedom-to-operate analyses before initiating related R&D programs.
What to do next
- Monitor for updates
Archived snapshot
Apr 7, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Anti-follicle stimulating hormone receptor antibodies
Grant US12595293B2 Kind: B2 Apr 07, 2026
Assignee
The Wistar Institute
Inventors
Alfredo Perales-Puchalt, David B. Weiner
Abstract
The present invention relates to an isolated antibody or antigen binding fragment thereof that bind specifically to the Follicle Stimulating Hormone Receptor (FSHR). Also provided are methods for treating a disease in a subject comprising administering to the subject an isolated antibody or antibody fragment thereof that binds FSHR.
CPC Classifications
C07K 16/2869 A61K 45/06 A61K 47/6803 A61K 47/6849 A61K 2039/505 A61K 2039/54 A61P 35/00
Filing Date
2019-08-09
Application No.
17267331
Claims
14
Related changes
Get daily alerts for USPTO Patent Grants - Therapeutics (A61P)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Grants - Therapeutics (A61P) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.